Recommendation Push
relevant
information on acquisi-
tion programs out to industry as soon as possible and encourage full and open competition. Obtain intellectual property rights and incentivize dual use of facilities.
LL_699: Regular engagement with the systems and software development contractors resulted in increased ROI and added value to the end product.
Background With dwindling resources, program man- agers (PMs) need to investigate ways to do more with less. One way to do this is to meet regularly with systems and software development contractors to discuss how to add value to the program and increase the return on investment.
Recommendation Be sure to engage systems or software development contractors regularly to discuss and implement potential ways of increasing ROI and adding value to the end product. Te contractors may have insight and ideas that may not occur to the program management office.
SCIENCE AND TECHNOLOGY LL_301: To have a successful prod- uct transition to a program of record (POR), technology transfer agreements (TTAs) need to include a well-devel- oped integration strategy.
Background Te Army Materiel
Systems Analy-
sis Activity’s Science and Technology Transition Study, released in May 2013, identified POR acquisition strategy as having the second most frequent impact on transition. Additionally, those pro- grams and products that transitioned to POR tended to have significantly detailed TTAs. Analysis of the integration strategy
LEVERAGING LARS
An automotive logistics assistance representative (LAR) with the U.S. Army TACOM Life Cycle Management Command works on a vehicle issue at Bagram Airfield, Afghanistan. Lessons-learned data indicate that leveraging LARs as part of maintenance plans can reduce the costs associated with maintaining a large FSR footprint. (Photo by Summer Barkley)
section showed that 83 percent that had significant detail produced positive impacts for POR transition.
Recommendation Require a fully developed integra- tion strategy in TTAs, as described in the Defense Acquisition University’s template
at
https://acc.dau.mil/
CommunityBrowser.aspx?id=22757. It is especially important to identify the level of PM commitment and the POR funding designated for product transi- tion and integration. Also, require that POR acquisition strategy include tech- nology insertion as part of the overall program from inception. Te contract- ing approach detailed in the strategy must support technology insertion.
MEDICINE LL_204: Initiate Phase 2 clinical trials before Milestone B to mitigate risk of an acquisition program baseline (APB)
deviation for the program during the engineering and manufacturing devel- opment (EMD) phase.
Background Medical programs that must go through the clinical trial process of the U.S. Food and Drug Administration (FDA) are inherently
risky. Te FDA typically
requires multiple clinical trials before it will grant licensure. Generally there is a requirement that a medical acquisition program conduct Milestone B before initi- ating Phase 2 clinical trials. However, there is still considerable risk and uncertainty in the Phase 2 trials, which has resulted in APB deviations for several programs.
Recommendation Initiating Phase 2 clinical trials before Milestone B mitigates risk of an APB deviation for the program. During this period, the PM can incorporate the les- sons learned during Phase 2 clinical trials
ASC.ARMY.MIL 35
ACQUISITION
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184
